MorphoSys eyes commercialisation

Fresh from a successful initial public share offering (IPO) on Nasdaq, MorphoSys AG is progressing plans for the potential commercialisation in the US of its first wholly-owned product – an antibody therapeutic for aggressive lymphoma.

Full text available to subscribers only. Click here for information on subscribing to MedNous.